Cargando…

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer

Overexpression of the human epidermal growth factor receptor-2 (HER2) in breast cancer strongly correlates with aggressive tumors and poor prognosis. Recently, a positive correlation between HER2 and MIF (macrophage migration inhibitory factor, a tumor-promoting protein and heat-shock protein 90 (HS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schulz, R, Streller, F, Scheel, A H, Rüschoff, J, Reinert, M-C, Dobbelstein, M, Marchenko, N D, Moll, U M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040658/ https://www.ncbi.nlm.nih.gov/pubmed/24384723 http://dx.doi.org/10.1038/cddis.2013.508

Ejemplares similares

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

Expression of MIF and c-erbB-2 in endometrial cancer
por: XIAO, WEI, et al.
Publicado: (2016)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
por: Goren, D., et al.
Publicado: (1996)

Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
por: Olayioye, Monilola A
Publicado: (2001)

HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
por: Khan, A N, et al.
Publicado: (2006)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance
por: Cheng, Guoxiong, et al.
Publicado: (2019)

Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?
por: Metges, J-P, et al.
Publicado: (2006)

The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling
por: Moreira Sousa, Cristovão, et al.
Publicado: (2013)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
por: Schulz, Ramona, et al.
Publicado: (2012)

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
por: Schulz, Ramona, et al.
Publicado: (2012)

HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
por: Zhang, Yi, et al.
Publicado: (2009)

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer
por: Chen, Dong, et al.
Publicado: (2021)

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability
por: Lam, Prudence B, et al.
Publicado: (2008)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2006)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2008)

Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
por: Jian, Wen, et al.
Publicado: (2020)

A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors
por: El-Gamal, Mohammed I., et al.
Publicado: (2021)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
por: Landgraf, Ralf
Publicado: (2007)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation
por: Larsen, SS, et al.
Publicado: (2000)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
por: Li, Dun, et al.
Publicado: (2016)

Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure
por: Szmit, Sebastian, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fr7pfforqdq4gnqhvkul6e0mmq